Brilinta ticagrelor regulatory update

The European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) released updated guidelines for myocardial revascularization that include two new antiplatelet options since the guidelines were last issued in 2005, including one that is still under review in Europe. Efient prasugrel from Eli Lilly and Daiichi Sankyo was approved in Europe last year, while Brilinta ticagrelor from AstraZeneca is still under review. ESC included both products as treatment options for patients with ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI). ...